Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate
Background: The impact of maternal tenofovir disoproxil fumarate (TDF) use on infant bone mass has not been well studied. Methodology: Two groups of HIV-exposed, uninfected newborns >36 weeks gestational age [GA] were enrolled in this substudy of the US multisite Pediatric HIV AIDS Cohort Study. The TDF group included infants whose mothers used ≥8 weeks…